Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer
The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.
Authors
- David R. Fogelman (ORCID: https://orcid.org/0000-0002-4063-189X)
- Rishi Surana (ORCID: https://orcid.org/0000-0002-8471-9236)
- Brandon G. Smaglo (ORCID: https://orcid.org/0000-0002-8814-8004)
- Florencia McAllister (ORCID: https://orcid.org/0000-0002-9915-0943)
- Ryan W. Huey (ORCID: https://orcid.org/0000-0002-7887-8484)
- Jason A. Willis (ORCID: https://orcid.org/0000-0001-8238-8552)
- Fen Saj (ORCID: https://orcid.org/0000-0003-0102-1789)
- H. Zhu
- Dan Zhao
- So Jung Hong
- Lianchun Xiao
- Robert A Wolff
- S. Pant
- J Jack Lee
- M Pia Morelli
- S Daniel Haldar
- Channing Der
- Michael Overman
- Anirban Maitra
Institutions
- University of North Carolina at Chapel Hill (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1093/oncolo/oyag071
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pancreatic Cancer Action Network
- Pfizer